Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls

International Journal of Eating Disorders

Volumn 41, Issue 5, 2008, Pages 432-438

  Storch, Caroline Henrike ^a   Nikendei, Christoph ^a   Schild, Sandra ^a   Haefeli, Walter Emil ^a   Weiss, Johanna ^a   Herzog, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ABCB1; Anorexia nervosa; Drug therapy; Drug transport; P glycoprotein

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123;

ADULT; ANOREXIA NERVOSA; ARTICLE; BODY MASS; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; BIOLOGICAL AVAILABILITY; BRAIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; METABOLIC CLEARANCE RATE; MONOCYTES; P-GLYCOPROTEIN; PSYCHOTROPIC DRUGS; REFERENCE VALUES; RNA, MESSENGER;

EID: 45749086147     PISSN: 02763478     EISSN: 1098108X     Source Type: Journal    
DOI: 10.1002/eat.20519     Document Type: Article

References (52)

1. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 2003;55:3-29.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
3. Wikinsi S. Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. The role of P-glycoprotein. Vertex 2005:16:438-441.
4. Merino V, Jimenez-Torres NV, Merino-Sanjuan M. Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr Drug Deliv 2004;1:203-212.
5. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004;78:21-25.
6. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-153.
7. Zipfel S, Löwe B, Reas DL, Deter HC, Herzog W. Long-term prognosis in anorexia nervosa: Lessons from a 21-year follow-up study. Lancet 2000;355:721-722.
8. Bulik CM, Reba L, Siega-Riz AM, Reichborn-Kjennerud T. Anorexia nervosa: Definition, epidemiology, and cycle of risk. Int J Eat Disord 2005;37:S2-S9.
9. Yager J, Andersen AE. Anorexia nervosa. N Engl J Med 2005;353:1481-1489.
10. Deter HC, Herzog W. Anorexia nervosa in a long-term perspective: Results of the Heidelberg-Mannheim Study. Psychosom Med 1994;56:20-27.
11. Löwe B, Zipfel S, Buchholz C, Dupont Y, Reas DL, Herzog W. Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychol Med 2001;31:881-890.
12. Herzog W, Deter HC, Fiehn W, Petzold E. Medical findings and predictors of long-term physical outcome in anorexia nervosa: A prospective, 12-year follow-up study. Psychol Med 1997;27:269-279.
13. Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. Curr Opin Psychiatry 2006;19:389-394.
14. Peterson CB, Mitchell JE. Psychosocial and pharmacological treatment of eating disorders: A review of research findings. J Clin Psychol 1999;55:685-697.
15. McIntosh VVW, Jordan J, Carter FA, Luty SE, McKenzie JM, Bulik CM, et al. Three psychotherapies for anorexia nervosa: A randomized, controlled trial. Am J Psychiatry 2005;162:741-747.
16. Practice guideline for the treatment of patients with eating disorders (revision): American Psychiatric Association Work Group on Eating disorders. Am J Psychiatry 2000;157(Suppl 1):1-39.
17. National Institute for Clinical Excellence (2004) Eating disorders - Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Available online at: http://www.nice.org. uk. Accessed June 6, 2007.
18. Mitchell JE, de Zwaan M, Roerig JL. Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord 2003;2:17-29.
19. Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: An open label trial. Int J Eat Disord 2002;32:146-154.
20. Wang TS, Chou YH, Shiah IS. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:306-309.
21. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998;155:548-551.
22. Gorwood P. Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am J Pharmacogenomics 2004;4:9-17.
23. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001;49:644-652.
24. Ferguson CP, La Via MC, Crossan PJ, Kaye WH. Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 1999;25:11-17.
25. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA 2006;295:2605-2612.
26. Weiss J, Dormann SMG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204.
27. Naessen S, Carlström K, Glant R, Jacobsson H, Hirschberg AL. Bone mineral density in bulimic women - Influence of endocrine factors and previous anorexia. Eur J Endocrinol 2006;155:245-251.
28. Monteleone P, Luisi M, Colurcio B, Casarosa E, Monteleone P, Ioime R. Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosom Med 2001;63:62-68.
29. Mitchell JE, Crow S. Medical complications of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry 2006;19:438-443.
30. Nakai Y, Hamagaki S, Takagi R, Taniguchi A, Kurimoto F. Plasma concentrations of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in patients with anorexia nervosa. J Clin Endocrinol Metab 1999;84:1226-1228.
31. Bauer B, Hartz AMS, Miller DS. TNF-α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2006;71:667-675.
32. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005;70:949-958.
33. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association (APA), Washington DC, 4th ed., 1994.
34. Wittchen HU, Zaudig M, Fydrich T. Strukturiertes Klinisches Interview für DSM-IV (SKID-I und SKID-II). Hogrefe: Göttingen, 1997.
35. Fichter MM, Herpertz S, Quadflieg N, Herpertz-Dahlmann B. Structured interview for anorexic and bulimic disorders for DSM-IV and ICD-10: Updated (third) revision. Int J Eat Disord 1998;24:227-249.
36. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: A key regulator of xenobiotics metabolism. Endocr Rev 2002;23:687-702.
37. ATC/DDD Index 2007; WHO collaborating centre for drug statistics methodology. Available online at: http://www.whocc.no/atcddd/. Accessed June 6, 2007.
38. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 2003;42:59-98.
39. Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, et al. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Dispos 2003;31:1251-1254.
40. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, Iansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551-557.
41. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther 2006;317:1012-1018.
42. Pawlik A, Bakiewicz-Masiuk M, Machaliski B, Safranow K, Gawroska-Szklarz B. Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. J Pharm Pharmacol 2005;57:1421-1425.
43. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 2004;21:1284-1293.
44. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 2006;97:1198-1204.
45. Suzuki T, Zhao YL, Nadai M, Naruhashi K, Shimizu A, Takagi K, et al. Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 2006;79:455-461.
46. Fukuda H, Arai M, Soh T, Yamauchi N, Hattori MA. Progesterone regulation of the expression and function of multidrug resistance type I in porcine granulosa cells. Reprod Toxicol 2006;22:62-68.
47. Mehler PS, Lezotte D, Eckel R. Lipid levels in anorexia nervosa. Int J Eat Disord 1998;24:217-221.
48. Matzkin VB, Geissler C, Coniglio R, Selles J, Bello M. Cholesterol concentrations in patients with anorexia nervosa and in healthy controls. Int J Psychiatr Nurs Res 2006;11:1283-1293.
49. Case T, Lemieux S, Kennedy SH, Lewis GF. Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. Int J Eat Disord 1999;25:187-193.
50. Weinbrenner T, Züger M, Jacoby GE, Herpertz S, Liedtke R, Sudhop T, et al. Lipoprotein metabolism in patients with anorexia nervosa: A case-control study investigating the mechanisms leading to hypercholesterolaemia. Br J Nutr 2004;91:959-969.
51. Ohwada R, Hotta M, Oikawa S, Takano K. Etiology of hypercholesterolemia in patients with anorexia nervosa. Int J Eat Disord 2006;39:598-601.
52. Deter HC, Herzog W. Langzeitverlauf der Anorexia nervosa. Vandenhoeck & Ruprecht: Göttingen, 1995, p. 95.